Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...

Larimar Therapeutics' CTI-1601 offers hope for Friedreich's ataxia patients, with promising trial results. Check out why LRMR ...

Acting Manhattan Supreme Court Justice Anar Rathod Patel last week denied a motion to dismiss from defendants Reata and Biogen, finding that fact questions remained.

Larimar Therapeutics (NASDAQ:LRMR) was started at outperform by Wedbush based on the company’s drug candidate nonlabofusp for ...

A Friedreich ataxia specialist discusses how the typical clinical presentation of Friedreich's Ataxia includes early onset with symptoms such as ataxia and sensory loss, while also examining the ...

Panelists discuss how the differential diagnosis for Friedreich's Ataxia involves distinguishing it from other ataxias, the ...

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and ...

More than three hundred kids in Oklahoma are on the waiting list right now to get their wishes granted by the Make-A-Wish ...

To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video ...

Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products ...

(RTTNews) - Biohaven Ltd. (BHVN) Monday said its pivotal study of troriluzole in Spinocerebellar Ataxia (SCA) met its primary goal. In the pre-market trade, the company's shares were rising about ...

Larimar will present three posters during the conference, one of which will also be presented as an oral presentation. The poster presentations are as follows: Effect of nomlabofusp administration on ...